Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Analyst/Investor Day September 30, 2025 2:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Nadia Waheed - Chief Medical Officer Jeffrey Heier, - Chief Scientific Officer Namrata Saroj - Chief Business Officer Jay Robins Peter Kaiser - Chief Development Officer William Slattery - Vice President of Investor Relations Conference Call Participants Arshad Khanani - Sierra Eye Associates Eleonora Lad Adnan Tufail Patricio Schlottmann Tara Bancroft - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Presentation Operator All right.

BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about October 1, 2025, subject to the satisfaction of customary closing conditions.

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Presentation Unknown Analyst Well, welcome Pravin. Great to have you here.

Ocular Therapeutix (OCUL -2.83%), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant widening in net loss due to increased research and marketing investments.

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Pravin U. Dugel - Executive Chairman, President & CEO William S.

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.24 per share a year ago.

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.

The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.

BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.

BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April: